Objective: Anticoagulants have been approved and used for decades as highly effective blood thinners. The objective of this study is to analyze the clinical trials in order to determine if the Watchman reduces the risk of stroke in patients with atrial fibrillation compared to those prescribed the traditional anticoagulants. This will contribute to the current body of knowledge and possibly provide beneficial clinical guidance with respect to providing an alternative option for those suffering from non-valvular Atrial fibrillation. Methods: A systematic literature search through the Saint James School of Medicine library resources as well as PubMed, Medscape, Google Scholar was conducted. Studies were included if the literature examined the comparison between the Watchman device and four specific anticoagulants (Xarelto, Eliquis, Pradaxa, and Warfarin) in association with reduction of risks of strokes in an atrial fibrillation population. The study includes a qualitative sub-analysis to explore additional clinical aspects that may affect risk of stroke and response of treatment. Results: Outcomes were significant for similar stroke occurrence, when compared to published clinical trials. Alternatively, there was a significant reduction in risk of bleeding and all-cause mortality in the Watchman? device compared to traditional NOACs and warfarin. While examining the studies and trials, overall, the Watchman? device offers a better long-term outcome therapy for non-valvular atrial fibrillation populations who are not possibilities for extended anticoagulation. The studies used for analysis examining the dosage found higher fatality with increased use of NOACs and more hospitalizations with decreased use. Conclusion: From the presented data, it is safe to say that the Watchman? device is a viable and effective alternative for stroke prophylaxis in certain patient populations. Compared to traditional anticoagulant therapies for non-valvular atrial fibrillation, these studies suggest that the Watchman? device can reduce bleeding time and, in most cases, the risk of stroke is less than or equal to traditional anti-coagulants.
References
[1]
U.S. Food and Drug Administration (2015) FDA Approves Watchman LAA Closure Technology. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P130013
[2]
January, C.T., Wann, L.S., Alpert, J.S., Calkins, H., Cigarroa, J.E., Cleveland Jr., J.C. and Sotoodehnia, N. (2014) 2014 AHA/ACC/HRS Guidelines for the Management of Patients with Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology, 64, e1-e76. https://doi.org/10.1161/CIR.0000000000000041
[3]
Schotten, U., Verheule, S., Kirchhof, P. and Goette, A. (2011) Pathophysiological Mechanisms of Atrial Fibrillation: A Translational Appraisal. Physiological Reviews, 91, 265-325. https://pubmed.ncbi.nlm.nih.gov/21248168/ https://doi.org/10.1152/physrev.00031.2009
[4]
Scalvini, S., Zanelli, E., Martinelli, G., Baratti, D., Giordano, A. and Glisenti, F. (2005) Cardiac Event Recording Yields More Diagnoses than 24-Hour Holter Monitoring in Patients with Palpitations. Journal of Telemedicine and Telecare, 11, 14-16. https://pubmed.ncbi.nlm.nih.gov/16035979/ https://doi.org/10.1258/1357633054461930
[5]
Park, J., Seok, H.S., Kim, S.S. and Shin, H. (2022) Photoplethysmogram Analysis and Applications: An Integrative Review. Frontiers in Physiology, 12, Article ID: 808451. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920970/ https://doi.org/10.3389/fphys.2021.808451
[6]
Yaghi, S., Song, C., Gray, W.A., Furie, K.L., Elkind, M.S. and Kamel, H. (2015) Left Atrial Appendage Function and Stroke Risk. Stroke, 46, 3554-3559. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659748/ https://doi.org/10.1161/STROKEAHA.115.011273
[7]
Regazzoli, D., Ancona, F., Trevisi, N., et al. (2015) Left Atrial Appendage: Physiology, Pathology, and Role as a Therapeutic Target. BioMed Research International, 2015, Article ID: 205013. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508372/ https://doi.org/10.1155/2015/205013
[8]
Lip, G.Y., Nieuwlaat, R., Pisters, R., Lane, D.A. and Crijns, H.J. (2010) Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach: The Euro Heart Survey on Atrial Fibrillation. Chest, 137, 263-272. https://pubmed.ncbi.nlm.nih.gov/19762550/ https://doi.org/10.1378/chest.09-1584
[9]
Zhao, M., Zhao, M., Hou, C.R., et al. (2022) Comparative Analysis of Left Atrial Appendage Closure Efficacy and Outcomes by CHA2DS2-VASc Score Group in Patients with Non-Valvular Atrial Fibrillation. Frontiers in Cardiovascular Medicine, 9, Article ID: 905728. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353551/ https://doi.org/10.3389/fcvm.2022.905728
[10]
Manzano-Fernández, S., López-Cuenca, A., Januzzi, J.L., et al. (2012) Usefulness of β-Trace Protein and Cystatin C for the Prediction of Mortality in Non ST Segment Elevation Acute Coronary Syndromes. American Journal of Cardiology, 110, 1240-1248. https://pubmed.ncbi.nlm.nih.gov/22818840/ https://doi.org/10.1016/j.amjcard.2012.06.027
[11]
Chung, M.K., Eckhardt, L.L., Chen, L.Y., et al. (2020) Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement from the American Heart Association. Circulation, 141, e750-e772. https://pubmed.ncbi.nlm.nih.gov/32148086/ https://doi.org/10.1161/CIR.0000000000000748
[12]
Patel, M.R., Mahaffey, K.W., Garg, J., et al. (2011) Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. The New England Journal of Medicine, 365, 883-891. https://pubmed.ncbi.nlm.nih.gov/21830957/
[13]
Rutherford, O.W., Jonasson, C., Ghanima, W., Söderdahl, F. and Halvorsen, S. (2020) Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Atrial Fibrillation: A Nationwide Cohort Study. European Heart Journal—Cardiovascular Pharmacotherapy, 6, 75-85. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073510/ https://doi.org/10.1093/ehjcvp/pvz086
[14]
Li, X., Keshishian, A., Hamilton, M., et al. (2018) Apixaban 5 and 2.5 mg Twice-Daily versus Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation Patients: Comparative Effectiveness and Safety Evaluated Using a Propensity-Score-Matched Approach. PLOS ONE, 13, e0191722. https://pubmed.ncbi.nlm.nih.gov/29373602/ https://doi.org/10.1371/journal.pone.0191722
[15]
Siontis, K.C., Zhang, X., Eckard, A., et al. (2018) Outcomes Associated with Apixaban Use in Patients with End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation, 138, 1519-1529. https://pubmed.ncbi.nlm.nih.gov/29954737/ https://doi.org/10.1161/CIRCULATIONAHA.118.035418
[16]
Holmes, D.R., Doshi, S.K., Kar, S., et al. (2015) Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. Journal of the American College of Cardiology, 65, 2614-2623. https://pubmed.ncbi.nlm.nih.gov/26088300/ https://doi.org/10.1016/j.jacc.2015.04.025
[17]
Koifman, E., Lipinski, M.J., Escarcega, R.O., et al. (2016) Comparison of Watchman Device with New Oral Anti-Coagulants in Patients with Atrial Fibrillation: A Network Meta-Analysis. International Journal of Cardiology, 205, 17-22. https://pubmed.ncbi.nlm.nih.gov/26709135/ https://doi.org/10.1016/j.ijcard.2015.11.181
[18]
Patel, M.R., Mahaffey, K.W., Garg, J., et al. (2011) Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. The New England Journal of Medicine, 365, 883-891. https://pubmed.ncbi.nlm.nih.gov/21830957/
[19]
Panaich, S.S. and Holmes, D.R. (2017) Atrial Fibrillation Incidence and Anticoagulation Use. JAMA Cardiology, 2, 895-896.
[20]
Holmes, D.R., Kar, S., Price, M.J., et al. (2014) Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients with Atrial Fibrillation versus Long-Term Warfarin Therapy: The PREVAIL Trial. Journal of the American College of Cardiology, 64, 1-12. https://pubmed.ncbi.nlm.nih.gov/24998121/ https://doi.org/10.1016/j.jacc.2014.04.029
[21]
Seiffge, D.J., Paciaroni, M., Wilson, D., et al. (2019) Direct Oral Anticoagulants versus Vitamin K Antagonists after Recent Ischemic Stroke in Patients with Atrial Fibrillation. Annals of Neurology, 85, 823-834. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563449/ https://doi.org/10.1002/ana.25489
[22]
Crader, M., Johns, T. and Arnold, J.K. (2020, May 5) Warfarin Drug Interactions. StatPearls Publishing, Treasure Island. https://www.ncbi.nlm.nih.gov/books/NBK441964/
[23]
Farmakis, D., Davlouros, P., Giamouzis, G., et al. (2018) Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing. Cardiology, 140, 126-132. https://pubmed.ncbi.nlm.nih.gov/29975925/ https://doi.org/10.1159/000489922
